| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
a Department of Human Genetics, Baylor College of Medicine, Houston, Texas, USA;
b Department of Blood and Marrow Transplantation,
c Department of Biostatistics, and
d Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Key Words. Acute myeloid leukemia • CXCR4 • NOD/SCID • Engraftment
Michael Andreeff, M.D., Ph.D., Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, Texas 77030, USA. Telephone: 713-792-7260; Fax: 713-794-4747, e-mail: mandreef{at}mdanderson.org
The aim of this study was to investigate factors influencing the engraftment potential of acute myeloid leukemia (AML) CD34+ cells in nonobese diabetic/ severe combined immunodeficiency (NOD/SCID) mice. We examined the relationship between engraftment, CXCR4 expression on CD34+ and CD34+CD38- cells, and patient (Pt) clinical/laboratory characteristics in 44 samples from 11 Pts. Engraftment, evaluated by Southern blot and CD45 flow cytometric analyses, was observed in murine bone marrow of 6 of 11 Pt samples, ranging from 0.1% to 73.9% by Southern blot and from 0.1%-36.8% by flow cytometry. Poor Pt prognosis was inversely correlated with engraftment; the median overall survival was 95.9 weeks for Pts whose cells did not engraft and 26.1 weeks for those whose cells did engraft (p = 0.012, log-rank test). No other clinical/laboratory variable predicted engraftment. No correlation between the level of CXCR4 expression on AML cells and engraftment was observed. Cells with virtually absent CXCR4 expression were able to engraft, and cells from two Pts with high expression levels of CXCR4 did not engraft. Furthermore, anti-CXCR4 antibody failed to block the engraftment of AML cells into NOD/SCID mice. In conclusion, we demonstrated that CXCR4 is not critical for the engraftment of AML CD34+ cells in NOD/SCID mice. The model may, however, reflect the clinical course of the disease.
This article has been cited by other articles:
|
|
 |
|
  A. C. Spoo, M. Lubbert, W. G. Wierda, and J. A. Burger CXCR4 is a prognostic marker in acute myelogenous leukemia Blood, January 15, 2007; 109(2): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kalinkovich, S. Tavor, A. Avigdor, J. Kahn, A. Brill, I. Petit, P. Goichberg, M. Tesio, N. Netzer, E. Naparstek, et al. Functional CXCR4-Expressing Microparticles and SDF-1 Correlate with Circulating Acute Myelogenous Leukemia Cells. Cancer Res., November 15, 2006; 66(22): 11013 - 11020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Burger and T. J. Kipps CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment Blood, March 1, 2006; 107(5): 1761 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pearce, D. Taussig, K. Zibara, L.-L. Smith, C. M. Ridler, C. Preudhomme, B. D. Young, A. Z. Rohatiner, T. A. Lister, and D. Bonnet AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML Blood, February 1, 2006; 107(3): 1166 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, and G. J. Schuurhuis High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clin. Cancer Res., September 15, 2005; 11(18): 6520 - 6527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Monaco, J. W. Belmont, M. Konopleva, M. Andreeff, S. Tavor, I. Petit, O. Kollet, and T. Lapidot Correlation between CXCR4 and Homing or Engraftment of Acute Myelogenous Leukemia Cancer Res., September 15, 2004; 64(18): 6832 - 6833. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
